Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
5e5 of anti-Siglec-3 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human Siglec-3, His Tag (Cat. No. CD3-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Loaded Siglec-3 MAb (Mouse IgG1) on AMC Biosensor, can bind Human Siglec-3 Protein, Llama IgG2b Fc Tag (Cat. No. CD3-H5259) with an affinity constant of 0.365 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Gemtuzumab ozogamicin | WAY-CMA-676; CL-555201; CMA-676; CDP-771; hP67.6-calicheamicin | Approved | Pfizer Inc, Ucb Sa | Mylotarg | EU | Leukemia, Myeloid, Acute | Pfizer Europe Ma Eeig | 2008-01-18 | Leukemia; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Lintuzumab-gelonin conjugate | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details | |
| Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid) | Clinical | Wuhan Bio-Raid Biotechnology | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) | Phase 1 Clinical | University Of California San Diego | Leukemia, Myeloid, Acute | Details | |
| ICG-136 | ICG-136; 123b-33bcCAR | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33 CAR-NK cell therapy (Sichuan Kelun-Biotech) | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Details | |||
| CD33xCD3 Bispecific Antibody (Y-mAbs Therapeutics) | Y-Mabs Therapeutics Inc | Details | |||
| JNJ-67571244 | JNJ-67571244; JNJ-67371244; JNJ-1244 | Johnson & Johnson | Details | ||
| OXS-3550 | OXS-3550-TriKE; GTB-3550; OXS-3550; OXIS-3550; 161533-TriKE; 161533 TriKE | Oxis Biotech, University Of Minnesota | Details | ||
| IM73 chimeric antigen receptor T cell therapy | IM-73-CAR-T | Beijing Immunochina Medical Science & Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Emerfetamab | AMG-673; AMG673 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
| AL-003 | AL-003 | Phase 1 Clinical | Abbvie Inc, Alector | Alzheimer Disease | Details |
| CLL1+CD33 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CD33 CAR-T Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CD33 CAR T Cells(Beijing Boren Hospital) | Phase 2 Clinical | Beijing Gao Boren Hospital Co Ltd | Leukemia; Neoplasms; Leukemia, Myeloid, Acute | Details | |
| PRGN-3006 | PRGN-3006 | Phase 1 Clinical | Precigen Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| Lintuzumab Ac-225/Venetoclax | Phase 1 Clinical | Actinium Pharmaceuticals Inc | Leukemia, Promyelocytic, Acute | Details | |
| Vixtimotamab | T-564; AMV-564 | Phase 1 Clinical | Amphivena Therapeutics Inc | Solid tumours; Myelodysplastic Syndromes | Details |
| CLL1-CD33 cCART cell therapy (iCell Gene Therapeutics) | CLL1-CD33-cCAR | Phase 1 Clinical | Chengdu Military General Hospital | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Myeloid, Acute | Details |
| Lintuzumab Ac-225 (Actinium Pharmaceuticals) | 225Ac-HuM-195; HuM195-Ac-225; AC225-MOAB-M195 | Phase 2 Clinical | Pdl Biopharma Inc | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| BI-836858 | BI-836858 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| CD123-CD33 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Neoplasms; Myeloproliferative Disorders; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details | ||
| Anti-CD33/CLL1 CAR-NK Cell Therapy | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details | |
| anti-CD33 CAR T cells therapy（iCell Gene Therapeutics） | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details | |
| Eluvixtamab | MT-114; AMG-330 | Phase 1 Clinical | Amgen Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Legend Biotech Corp | Leukemia, Promyelocytic, Acute | Details | |
| CART-33 (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.
A-Z
